title: Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
abstract: This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5-40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p< 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<-50%) and non-responders (≥-50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H,n= 16) and those with lower values, Group H showed significantly decreased urinary albumin (p< 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome.
authors: Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan. m01084tm@jichi.ac.jp.
authors: Tomoko
authors: T
authors: Mizushige
authors: Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan. hkobori@iuhw.ac.jp.|Departments of Pharmacology and of Nephrology, School of Medicine, International University of Health and Welfare, Tokyo 107-0062, Japan. hkobori@iuhw.ac.jp.|Departments of Physiology and of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA. hkobori@iuhw.ac.jp.
authors: Hiroyuki
authors: H
authors: Kobori
authors: Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan. hitomi@med.kagawa-u.ac.jp.
authors: Hirofumi
authors: H
authors: Hitomi
authors: Department of Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan. youko.n@med.kagawa-u.ac.jp.
authors: Yoko
authors: Y
authors: Nishijima
authors: The Second Department of Internal Medicine, Toyama University School of Medicine, Toyama 930-0194, Japan. tomoda@med.u-toyama.ac.jp.
authors: Fumihiro
authors: F
authors: Tomoda
authors: The Second Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, Japan. smorimoto@endm.twmu.ac.jp.
authors: Satoshi
authors: S
authors: Morimoto
authors: Department of Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan. mkohno@med.kagawa-u.ac.jp.
authors: Masakazu
authors: M
authors: Kohno
authors: Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan. akira@med.kagawa-u.ac.jp.
authors: Akira
authors: A
authors: Nishiyama
mesh_terms: D000328:Adult; D000419:Albuminuria / Q000188:drug therapy / Q000473:pathology / Q000652:urine*; D000808:Angiotensinogen / Q000652:urine*; D054316:Biomarkers, Pharmacological / Q000652:urine; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000473:pathology / Q000652:urine*; D008875:Middle Aged; D011379:Prognosis; D013777:Tetrazoles / Q000008:administration & dosage
chemical_list: D054316:Biomarkers, Pharmacological; D007093:Imidazoles; D013777:Tetrazoles; D000808:Angiotensinogen; C437965:olmesartan; D003404:Creatinine
keywords: angiotensin receptor blocker; metabolic syndrome; prognostic marker of albuminuria reduction effects; renin-angiotensin system; urinary angiotensinogen